|
[1] CHEN L, HAN X. Anti-PD-1/PD-L1 therapy of humancancer:Past, present, and future[J]. J Clin Invest, 2015, 125 (9) :3384-3391.
|
|
[2] KIM JW, EDER JP. Prospects for targeting PD-1 and PD-L1in various tumor types[J]. Oncology, 2014, 3 (11 Suppl 3) :15-28.
|
|
[3] REBELATTO MC, MIDHA A, MISTRY A, et al. Development ofa programmed cell death ligand-1 immunohistochemical as-say validated for analysis of non-small cell lung cancer andhead and neck squamous cell carcinoma[J]. Diagn Pathol, 2016, 11 (1) :95-97.
|
|
[4] ROZALI EN, HATO SV, ROBINSON BW, et al. Programmeddeath ligand 2 in cancer-induced immune suppression[J].Clin Dev Immunol, 2012, 2012 (2) :656340.
|
|
[5] YOKOSUKA T, TAKAMATSU M, KOBAYASHIIMANISHI W, etal. Programmed cell death 1 forms negative costimulatory mi-croclusters that directly inhibit T cell receptor signaling by re-cruiting phosphatase SHP2[J]. J Exp Med, 2012, 209 (6) :1201-1217.
|
|
[6] HUI E, CHEUNG J, ZHU J, et al. T cell costimulatory receptorCD28 is a primary target for PD-1-mediated inhibition[J].Science, 2017, 355 (6332) :1428-1432.
|
|
[7] PATSOUKIS N, BROWN J, PETKOVA V, et al. Selective effectsof PD-1 on Akt and Ras pathways regulate molecular compo-nents of the cell cycle and inhibit T cell proliferation[J]. Sci Sig-nal, 2012, 5 (230) :46-50.
|
|
[8] CHAMOTO K, CHOWDHURY PS, KUMAR A, et al. Mitochon-drial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity[J]. ProcNatl Acad Sci U S A, 2017, 114 (5) :e761-e770.
|
|
[9] CHANG CH, QIU J, O'SULLIVAN D, et al. Metabolic competi-tion in the tumor microenvironment is a driver of cancer pro-gression[J]. Cell, 2015, 162 (6) :1229-1241.
|
|
[10] SPRANGER S, KOBLISH HK, HORTON B, et al. Mechanismof tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and prolif-eration of CD8 (+) T cells directly within the tumor microenvi-ronment[J]. J Immunother Cancer, 2014, 2 (1) :3-6.
|
|
[11] TAO LL, LAI X, WEI J. PD-1/PD-L signaling pathway inchronic hepatitis B[J]. J Clin Hepatol, 2016, 32 (12) :2373-2378. (in Chinese) 陶丽琳, 赖欣, 韦嘉. PD-1/PD-L信号通路在慢性HBV感染免疫反应中的作用[J].临床肝胆病杂志, 2016, 32 (12) :2373-2378.
|
|
[12] AHN J, BISHOP JA, RODEN RBS, et al. The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis[J]. La-ryngoscope, 2017, 128 (1) :e27-e32.
|
|
[13] TREHANPATI N, VYAS AK. Immune regulation by T regulatorycells in hepatitis B virus-related inflammation and cancer[J].Scand J Immunol, 2017, 85 (3) :175-181.
|
|
[14] PENG JP, SUN KW, WU YN, et al. Programmed cell death 1expression on HBV-specific CTLs induced by dendritic cellsin chronic hepatitis B patients[J]. J Clin Hepatol, 2012, 28 (12) :926-929. (in Chinese) 彭建平, 孙克伟, 伍玉南, 等.慢性乙型肝炎患者树突状细胞诱导的HBV特异性细胞毒性T淋巴细胞PD-1的表达[J].临床肝胆病杂志, 2012, 28 (12) :926-929.
|
|
[15] ZHU Q, CHENG BQ, LIN WG, et al. Study on relationship be-tween chronic hepatitis B HBVDNA and pd-1/pd-L1[J].Fujian Med J, 2018, 40 (1) :8-10. (in Chinese) 朱琪, 程变巧, 林伟国, 等.慢性乙型肝炎HBV DNA载量与PD-1/PD-L1表达相关性研究[J].福建医药杂志, 2018, 40 (1) :8-10.
|
|
[16] BUKH J. The history of hepatitis C virus (HCV) :Basic re-search reveals unique features in phylogeny, evolution and theviral life cycle with new perspectives for epidemic control[J].J Hepatol, 2016, 65 (1) :s2-s21.
|
|
[17] KONG LB, NAN YM, ZHANG YG, et al. Association of pro-grammed cell death-1 gene polymorphisms with chronic hep-atitis C virus infection and antiviral effect[J]. J Clin Hepatol, 2016, 32 (9) :1721-1724. (in Chinese) 孔令波, 南月敏, 张玉果, 等.程序性细胞死亡受体1基因多态性与慢性HCV感染及抗病毒疗效的关系[J].临床肝胆病杂志, 2016, 32 (9) :1721-1724.
|
|
[18] WEN X, LONG FJ, XIAO ZD, et al. PD-1/PD-L1 signalpathway participates in HCV F protein-induced T cell dys-function in chronic HCV infection[J]. Immunol Res, 2016, 64 (2) :412-423.
|
|
[19] ZHANG M, ZHANG L, LI H, et al. Circulating T follicular help-er cells are associated with rapid virological response in chron-ic hepatitis C patients undergoing peginterferon therapy[J].Int Immunopharmacol, 2016, 34:235-243.
|
|
[20] XIAO W, PEI JP, JI XW, et al. An overview of immunoregula-tory roles of PD-1/PD-L1 in HCV treatment[J]. Chin J DisControl Prev, 2017, 21 (2) :200-205. (in Chinese) 肖雯, 裴家平, 季晓伟, 等. HCV治疗中PD-1/PD-L1信号免疫调控作用的研究概况[J].中华疾病控制杂志, 2017, 21 (2) :200-205.
|
|
[21] ZHAI N, LI H, SONG H, et al. Hepatitis C virus induces MD-SCs-like monocytes through TLR2/PI3K/AKT/STAT3 signa-ling[J]. PLos One, 2017, 12 (1) :e0170516.
|
|
[22] SAAB S, RHEEM J, JIMENEZ M, et al. Curing hepatitis C in livertransplant recipients is associated with changes in immunosup-pressant use[J]. J Clin Transl Hepatol, 2016, 4 (1) :32-38.
|
|
[23] THAN NN, WIEGARD C, WEILER-NORMANN C, et al. Long-term follow-up of patients with difficult to treat type 1 auto-immune hepatitis on tacrolimus therapy[J]. Scand J Gastro-enterol, 2016, 51 (3) :329-336.
|
|
[24] LEONARDI GC, GAINOR JF, ALTAN M, et al. Safety of pro-grammed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disor-ders[J]. J Clin Oncol, 2018, 36 (19) :1905-1908.
|
|
[25] RUI ZL. Programmed cell death-1 and programmed celldeath-1 receptor on peripheral blood CD8+T lymphocytes inpatients with autoimmune hepatitis[J]. J Prac Hepatol, 2017, 20 (3) :352-353. (in Chinese) 芮志莲.自身免疫性肝炎患者外周血CD8+T淋巴细胞PD-1表达水平变化[J].实用肝脏病杂志, 2017, 20 (3) :352-353.
|
|
[26] ZHANG B, CHIKUMA S, HORI S, et al. Nonoverlapping rolesof PD-1 and FoxP3 in maintaining immune tolerance in a no-vel autoimmune pancreatitis mouse model[J]. Proc Natl AcadSci U S A, 2016, 113 (30) :8490-8495.
|
|
[27] AARSLEV K, DIGE A, GREISEN SR, et al. Soluble programmeddeath-1 levels are associated with disease activity and treatmentresponse in patients with autoimmune hepatitis[J]. Scand J Gas-troenterol, 2017, 52 (1) :93-99.
|
|
[28] GUTZMER R, KOOP A, MEIER F, et al. Programmed celldeath protein-1 (PD-1) inhibitor therapy in patients withadvanced melanoma and preexisting autoimmunity or ipili-mumab-triggered autoimmunity[J]. Eur J Cancer, 2017, 75 (1) :24-32.
|
|
[29] FU J, WANG H. Precision diagnosis and treatment of livercancer in China[J]. Cancer Lett, 2017, 41 (2) :78-83.
|
|
[30] CALDERARO J, ROUSSEAU B, AMADDEO G, et al. PD-L1expression in hepatocellular carcinoma:Relationship with clini-cal and pathological features[J]. Hepatology, 2016, 64 (6) :2038-2041.
|
|
[31] SHI S, RAO Q, ZHANG C, et al. Dendritic cells pulsed withexosomes in combination with PD-1 antibody increase the ef-ficacy of sorafenib in hepatocellular carcinoma model 1, 2[J].Transl Oncol, 2018, 11 (2) :250-258.
|
|
[32] LICHTENEGGER FS, ROTHE M, SCHNORFEIL FM, et al. Targe-ting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells[J]. Front Immunol, 2018, 9 (3) :85-90.
|
|
[33] HUANG A, ZHANG B, YAN W, et al. Myeloid-derived sup-pressor cells regulate immune response in patients with chron-ic hepatitis B virus infection through PD-1-induced IL-10[J]. J Immunol, 2014, 193 (11) :5461-5469.
|
|
[34] YANG L, ZHU XL, LI G. Expression of programmed death--ligand 1 in hepatocellular carcinoma and its clinical signifi-cance[J]. J Clin Hepatol, 2016, 32 (8) :1630-1634. (inChinese) 杨柳, 朱曦龄, 黎功.程序性死亡因子配体1在肝细胞癌中的表达及意义[J].临床肝胆病杂志, 2016, 32 (8) :1630-1634.
|
|
[35] HUANG F, WANG B, ZENG J, et al. MicroRNA-374b inhibitsliver cancer progression via down regulating programmed celldeath-1 expression on cytokine-induced killer cells[J]. On-col Lett, 2018, 15 (4) :66-69.
|
|
[36] FANG D, CHEN ZY. Diagnosis and treatment of hepatic alveo-lar echinococcosis[J]. J Clin Hepatol, 2017, 33 (5) :990-993. (in Chinese) 方丹, 陈哲宇.肝泡状棘球蚴病的诊断和治疗[J].临床肝胆病杂志, 2017, 33 (5) :990-993.
|
|
[37] HUANG SB, MI YY, LIU AQ, et al. The status and progres-sion in the diagnosis of hepatic echinococcosis[J]. Prog ModBiomed, 2016, 16 (4) :797-800. (in Chinese) 黄士波, 米圆圆, 刘爱琴, 等.肝包虫病的诊断现状及进展[J].现代生物医学进展, 2016, 16 (4) :797-800.
|
|
[38] ZHANG F, PANG N, ZHU Y, et al. CCR7 (lo) PD-1 (hi) CX-CR5 (+) CD4 (+) T cells are positively correlated with levelsof IL-21 in active and transitional cystic echinococcosis pa-tients[J]. BMC Infect Dis, 2015, 15 (1) :457-461.
|
|
[39] LI Y, XIAO Y, SU M, et al. Role of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients with cystic echi-nococcosis[J]. Exp Ther Med, 2016, 11 (1) :251-256.
|
|
[40] LA X, ZHANG F, LI Y, et al. Upregulation of PD-1 on CD4+CD25+T cells is associated with immunosuppression in liver ofmice infected with Echinococcus multilocularis[J]. Int Immu-nopharmacol, 2015, 26 (2) :357-366.
|
|
[41] SONG ZP, GUO D, CAI ZM, et al. Research progress of im-munobiology in organ xenotransplantation[J]. Ogran Trans-plantation, 2018, 9 (3) :236-238. (in Chinese) 宋宗培, 郭蝶, 蔡志明, 等.异种器官移植免疫生物学研究进展[J].器官移植, 2018, 9 (3) :236-238.
|
|
[42] de MARE-BREDEMEIJER EL, MANCHAM S, VERSTEGENMM, et al. Human graft-derived mesenchymal stromal cellspotently suppress alloreactive T-cell responses[J]. StemCells Dev, 2015, 24 (12) :1436-1447.
|
|
[43] SHI XL, MANCHAM S, HANSEN BE, et al. Counter-regula-tion of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction[J]. J Hepatol, 2016, 64 (6) :1274-1282.
|
DownLoad: